Methods and compositions to treat liver diseases and conditions
AssigneeAsociacióN Centro De InvestigacióN Cooperativa En Biociencias-Cic Biogune
InventorsMaria Luz MARTINEZ CHANTAR, Juan ANGUITA
Life of this patent
Estimating the term…
Abstract
Methods and compounds useful to treat diseases and conditions are provided. Methods of administering one or more microRNA-inhibitor compounds or one or more microRNA-enhancing compounds to cells, tissues, and/or subjects as a treatment for a disease or condition are provided.
Claims31
1-22. (canceled)
A method of increasing GNMT enzyme activity in a cell, the method comprising contacting the cell with an miRNA-inhibitor compound in an amount effective to increase GNMT enzyme activity in the cell and wherein the increase in GNMT enzyme activity reduces DNA hypermethylation in the cell.
24-26. (canceled)
(canceled)
37-40. (canceled)
42-52. (canceled)
A method of identifying an miRNA-modulating compound that alters an activity of one or both of miRNA-873-5p and miRNA-518d-5p in a cell, the method comprising
- (a) contacting a cell a candidate miRNA-modulating compound;
- (b) determining the amount of activity of one or both of miRNA-873-5p and miRNA-518d-5p in the cell;
- and
- (c) comparing the amount of activity determined for one or both of miRNA-873-5p and miRNA-518d-5p with a control amount of activity of miRNA-873-5p and miRNA-518d-5p, respectively, wherein a decrease in the amount of activity of one or both of miRNA-873-5p and miRNA-518d-5p in the contacted cell compared to the control amount of activity of miRNA-873-5p and miRNA-518d-5p, respectively identifies the candidate miRNA-modulating compound as an miRNA-inhibiting compound and wherein an increase in the amount of activity of one or both of miRNA-873-5p and miRNA-518d-5p in the contacted cell compared to the control amount of activity of miRNA-873-5p and miRNA-518d-5p, respectively identifies the candidate miRNA-modulating compound as an miRNA-enhancing compound.
55-56. (canceled)
58-60. (canceled)
A pharmaceutical composition, comprising at least one miRNA-modulating compound and a pharmaceutically acceptable carrier.
(canceled)
(canceled)
68-70. (canceled)
(canceled)
Dependencies are inferred from the claim text.